The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

By Joseph G. Yu, S. Javorschi, A. Hevener, Y. Kruszynska, R. A. Norman, M. Sinha, Jerrold M. Olefsky. Diabetes, 2002

735 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/8b295bd90af4d90f1de9a421d28263329407d1af

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Ralph DeFronzo
2. J. Díez
3. H. Fang
4. R. L. Judd
5. P. Ferré
6. P. Iglesias
7. Sushil Kumar Jain
8. A. Achari

In Molecular Biology

1. Ralph DeFronzo
2. H. Fang
3. R. L. Judd
4. P. Ferré
5. K. Bornfeldt
6. I. Tabas

In Physiology

1. Ralph DeFronzo
2. H. Fang
3. R. L. Judd
4. Lawrence J. Mandarino
5. H. Bays
6. Sushil Kumar Jain
7. A. Achari

Citations in the corpus

• Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. (2004, background): “Other indications that the thiazolidinediones have converted the dysfunctional fat cell in type 2 diabetics into a healthier fat cell include 1) inhibition of resistin, TNF , and PAI-1 gene expression in adipocytes and reduction in their circulating levels (127, 128, 160, 197, 228, 325, 326), and 2)”
• The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. (2004, background): “A number of articles have now shown that TZD treatment increases adiponectin expression and secretion in insulin-resistant humans and rodents (52,53).”
• The role of the novel adipocyte-derived hormone adiponectin in human disease. (2003, background): “During a hyperinsulinemic ‐ euglycemic glucose clamp, adiponectin levels were suppressed below basal levels in both diabetic and non-diabetic subjects ( 55 ).”
• Adiponectin: action, regulation and association to insulin sensitivity (2005, background): “Hyperinsulinaemia during a hyperinsulinemic euglycemic clamp has been shown to decrease circulating adiponectin levels, indicating that high levels of insulin might reduce plasma adiponectin concentrations (36,78).”
• Adiponectin: more than just another fat cell hormone? (2003, background): “Euglycemic-hyperinsulinemic clamp studies in both humans and rats (45) have shown that insulin infusion leads to decreased circulating adiponectin levels, consistent with the interpretation that insulin exerts an acute effect on adipocytes to decrease production and/or secretion of this adipocytokin”